NASDAQ:TCRX TScan Therapeutics (TCRX) Stock Price, News & Analysis $5.63 -0.01 (-0.18%) (As of 08/30/2024 04:00 PM ET) Add Compare Share Share Today's Range$5.40▼$5.7950-Day Range$5.53▼$7.4952-Week Range$2.14▼$9.69Volume218,800 shsAverage Volume224,950 shsMarket Capitalization$298.22 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get TScan Therapeutics alerts: Email Address TScan Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside113.1% Upside$12.00 Price TargetShort InterestHealthy3.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 13 Articles This WeekInsider TradingSelling Shares$951,885 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.36) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.59 out of 5 starsMedical Sector487th out of 933 stocksBiological Products, Except Diagnostic Industry76th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingTScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about TScan Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.02% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TScan Therapeutics has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCRX. Previous Next 2.6 News and Social Media Coverage News SentimentTScan Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for TCRX on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have sold 1,596.76% more of their company's stock than they have bought. Specifically, they have bought $56,100.00 in company stock and sold $951,885.00 in company stock.Percentage Held by InsidersOnly 2.76% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TScan Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TScan Therapeutics are expected to decrease in the coming year, from ($1.36) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about TScan Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceFREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportunities to DOUBLE their money... Now it's YOUR CHANCE to hunt MASSIVE gains like these with a professional trader for an ENTIRE WEEK... 100% FREE!Click here to join FREE >> About TScan Therapeutics Stock (NASDAQ:TCRX)TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More TCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRX Stock News HeadlinesAugust 28, 2024 | insidertrades.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Director Acquires $27,650.00 in StockAugust 28, 2024 | insidertrades.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Insider Sells $951,885.08 in StockSeptember 3, 2024 | Porter & Company (Ad)Obama’s final twist in Appalachia Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 30, 2024 | americanbankingnews.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Director Purchases $27,650.00 in StockAugust 29, 2024 | americanbankingnews.comBarbara Klencke Purchases 5,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockAugust 29, 2024 | finance.yahoo.comDirector of TScan Therapeutics Barbara Klencke Buys 18% More SharesAugust 29, 2024 | globenewswire.comTScan Therapeutics to Participate in Upcoming Investor ConferencesAugust 29, 2024 | americanbankingnews.comZoran Zdraveski Sells 164,686 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockSeptember 3, 2024 | Porter & Company (Ad)Obama’s final twist in Appalachia Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 28, 2024 | markets.businessinsider.comTScan Therapeutics (TCRX) Gets a Buy from Morgan StanleyAugust 15, 2024 | nasdaq.comExpert Outlook: TScan Therapeutics Through The Eyes Of 5 AnalystsAugust 13, 2024 | finanznachrichten.deTScan Therapeutics, Inc.: TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for TScan Therapeutics Amidst Strong Pipeline Progress and Robust Financial HealthAugust 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Aprea Therapeutics (APRE), TScan Therapeutics (TCRX)August 12, 2024 | investorplace.comTCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024August 12, 2024 | globenewswire.comTScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 2, 2024 | morningstar.comTScan Therapeutics Inc TCRXJune 14, 2024 | globenewswire.comTScan Therapeutics Announces Updates to its Board of DirectorsSee More Headlines Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/03/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCRX CUSIPN/A CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$15.00 Low Stock Price Target$10.00 Potential Upside/Downside+113.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,220,000.00 Net Margins-855.84% Pretax Margin-855.84% Return on Equity-59.83% Return on Assets-35.42% Debt Debt-to-Equity Ratio0.08 Current Ratio7.77 Quick Ratio7.77 Sales & Book Value Annual Sales$12.20 million Price / Sales24.39 Cash FlowN/A Price / Cash FlowN/A Book Value$4.82 per share Price / Book1.17Miscellaneous Outstanding Shares52,863,000Free Float51,404,000Market Cap$297.62 million OptionableNot Optionable Beta0.83 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Gavin MacBeath Ph.D. (Age 54)CEO & Director Comp: $650.17kDr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory BoardMr. Jason A. Amello (Age 56)Chief Financial Officer Mr. Leiden Dworak M.B.A.Principal Accounting Officer & TreasurerDr. Justin McCue Ph.D.Chief Technology OfficerMs. Ann HargravesSenior Vice President of Human ResourcesDr. Shrikanta Chattopadhyay M.D.Senior VP & Head of Translational MedicineMore ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPNkartaNASDAQ:NKTXVoyager TherapeuticsNASDAQ:VYGRFate TherapeuticsNASDAQ:FATECASI PharmaceuticalsNASDAQ:CASIView All CompetitorsInsiders & InstitutionsBarbara KlenckeBought 5,000 shares on 8/26/2024Total: $27,650.00 ($5.53/share)Barbara KlenckeBought 5,000 shares on 8/23/2024Total: $28,450.00 ($5.69/share)Zoran ZdraveskiSold 164,686 sharesTotal: $951,885.08 ($5.78/share)Troluce Capital Advisors LLCBought 92,832 shares on 8/15/2024Ownership: 0.176%The Manufacturers Life Insurance Company Bought 15,383 shares on 8/15/2024Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions TCRX Stock Analysis - Frequently Asked Questions How have TCRX shares performed this year? TScan Therapeutics' stock was trading at $5.83 on January 1st, 2024. Since then, TCRX stock has decreased by 3.4% and is now trading at $5.63. View the best growth stocks for 2024 here. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) issued its earnings results on Monday, August, 12th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. The business earned $0.54 million during the quarter, compared to analysts' expectations of $1.55 million. TScan Therapeutics had a negative net margin of 855.84% and a negative trailing twelve-month return on equity of 59.83%. When did TScan Therapeutics IPO? TScan Therapeutics (TCRX) raised $100 million in an initial public offering on Friday, July 16th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are TScan Therapeutics' major shareholders? TScan Therapeutics' top institutional shareholders include Great Point Partners LLC (1.78%), Marshall Wace LLP (0.58%), Bank of Montreal Can (0.23%) and Bank of New York Mellon Corp (0.22%). Insiders that own company stock include Lynx1 Capital Management Lp, David P Southwell, Timothy J Barberich, Barbara Klencke, Brian M Silver, Zoran Zdraveski and Gavin Macbeath. View institutional ownership trends. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCRX) was last updated on 9/3/2024 by MarketBeat.com Staff From Our PartnersFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredFREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportun...Monument Traders Alliance | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredKamala? Trump? _______? Think again. This play has delivered an annualized average gain of nearly 50% in just three months time… before every singl...The Freeport Society | SponsoredForget polls, focus on these 5 tickersWith all the geopolitical tensions in the world… all the inflation… all the expectations of a new round of Fed...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
